Boulding Mark Elliott
Boulding Mark Elliott, EVC, reported a transaction classified as exercise at PTC THERAPEUTICS, INC. involving 192.000000 shares for an estimated $0.00. Reported holdings after the transaction were 2267.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Oct 09, 2026
- Filing date
- Oct 13, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
PTCT price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001578852-26-000026 Stock Option (Right to Buy)
- Transaction date
- Oct 09, 2026 Filed Oct 13, 2026, 09:20 PM · 4d delay
- Shares
- 192 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 2,267 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
EXEC. VP AND CLO
- F1
This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, u…
- F3
This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares…
0 other transactions
0 recent txs